Literature DB >> 9239428

Cardiac disease in chronic uremia: clinical outcome and risk factors.

R N Foley1, P S Parfrey.   

Abstract

Cardiac disease is common and is the major killer in end-stage renal disease (ESRD). Cardiac failure is a highly malignant condition in ESRD patients. Cardiac failure mediates most of the adverse prognostic impact of ischemic heart disease. Left ventricular (LV) abnormalities are already present at initiation of dialysis therapy in approximately 80% of patients. These abnormalities (ie, systolic dysfunction in approximately 15%, LV dilatation with preserved systolic function in 30%, concentric LV hypertrophy [LVH] in 40%) independently predict ischemic heart disease and cardiac failure, and are the largest baseline predictor of mortality after 2 years on dialysis therapy. The associations between classical risk factors (eg, hyperlipidemia, smoking, hypertension) and cardiac outcomes in ESRD are inconsistent. "Uremic" risk factors represent a nascent, but potentially important field. In our prospective 10-year study of 433 patients starting renal replacement therapy, we identified the following as major independent risk factors for cardiac disease: (1) hypertension (concentric LVH, LV dilatation, ischemic heart disease, cardiac failure, inverse relationship with mortality); (2) anemia (LV dilatation, cardiac failure, death); and (3) hypoalbuminemia (ischemic heart disease, cardiac failure, death). Transplantation dramatically improved LV abnormalities, suggesting that a uremic environment is cardiotoxic. Multiple risk factors act in concert to produce cardiac disease in ESRD; many of these are avoidable, suggesting that the enormous burden of disease can be reduced considerably.

Entities:  

Mesh:

Year:  1997        PMID: 9239428     DOI: 10.1016/s1073-4449(97)70032-3

Source DB:  PubMed          Journal:  Adv Ren Replace Ther        ISSN: 1073-4449


  10 in total

Review 1.  Chronic renal disease.

Authors:  Malvinder S Parmar
Journal:  BMJ       Date:  2002-07-13

2.  Ischemia and inflammation on chronic kidney disease.

Authors:  Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2017-07-27       Impact factor: 5.952

3.  Aortic valve prosthesis selection in dialysis patients based on the patient's condition.

Authors:  Shinya Fukui; Mitsuhiro Yamamura; Masataka Mitsuno; Hiroe Tanaka; Masaaki Ryomoto; Yuji Miyamoto
Journal:  J Artif Organs       Date:  2012-02-26       Impact factor: 1.731

Review 4.  Volume control in treatment-resistant congestive heart failure: role for peritoneal dialysis.

Authors:  K E Broekman; S J Sinkeler; F Waanders; G L Bartels; G Navis; W M T Janssen
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

Review 5.  Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs.

Authors:  Hudaifa Alani; Asad Tamimi; Nihad Tamimi
Journal:  World J Nephrol       Date:  2014-11-06

6.  Heart failure severity scoring system and medical- and health-related quality-of-life outcomes: the HEMO study.

Authors:  Kelly V Liang; Francis Pike; Christos Argyropoulos; Lisa Weissfeld; Jeffrey Teuteberg; Mary Amanda Dew; Mark L Unruh
Journal:  Am J Kidney Dis       Date:  2011-05-06       Impact factor: 8.860

7.  Secondary hyperparathyroidism and target organs in chronic kidney disease.

Authors:  M Nikodimopoulou; S Liakos
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

Review 8.  Hemodialysis in elderly patients.

Authors:  W W Brown
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.266

9.  Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad.

Authors:  Mário Raimundo; José António Lopes
Journal:  Cardiol Res Pract       Date:  2011-02-20       Impact factor: 1.866

10.  The relative importance of frailty, physical and cardiovascular function as exercise-modifiable predictors of falls in haemodialysis patients: a prospective cohort study.

Authors:  Tobia Zanotto; Thomas H Mercer; Marietta L van der Linden; Robert Rush; Jamie P Traynor; Colin J Petrie; Arthur Doyle; Karen Chalmers; Nicola Allan; Ilona Shilliday; Pelagia Koufaki
Journal:  BMC Nephrol       Date:  2020-03-14       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.